Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?

As of Oct. 5, 2026, the iShares Biotechnology ETF (IBB) returned 38.0% over the trailing year, versus 17.4% for the iShares U.S. Healthcare ETF (IYH), but had a larger five-year maximum drawdown (35.7% vs. 17.9%). IYH charges a 0.37% expense ratio versus IBB’s 0.44% and yields 1.1% versus 0.2%; the article favors IYH as a diversified long-term foundation while presenting IBB as a higher-volatility option for investors confident in biotech momentum.

Analysis

The key portfolio distinction is not simply “diversified versus volatile”: IYH’s 14.6% LLY weight makes it meaningfully exposed to the GLP-1 trade, while its largest three holdings together create substantial single-name concentration. IBB’s 243 positions also overstate diversification at the top: its three largest holdings account for roughly 23% of assets. The funds therefore offer different concentration risks, not a clean concentrated-versus-broad split.

Contrarian signal: IBB’s sharp trailing-year lead has not translated into a five-year cumulative advantage in the supplied data. That weakens the case for extrapolating the recent biotech cycle as persistent alpha. Conversely, low reported betas should not be mistaken for low event risk: trial failures and regulatory decisions can create gap moves that monthly beta will understate. IYH may also be less defensive than its label suggests if LLY’s weight dominates sector returns.

Near term, biotech deal activity and FDA outcomes can sustain IBB momentum, but the 1–3 month path is catalyst- and positioning-sensitive; acquisition headlines are not evidence that broad portfolio earnings will rise. Over 6–18 months, drug-launch execution, pipeline productivity, and patent exposure matter more than ETF-level headline return. The relative-value thesis is falsified if IBB’s relative strength persists alongside improving fundamentals across its holdings, or if LLY weakness causes IYH to underperform despite broader healthcare resilience.

Key Decisions for Investors

• For a healthcare core, prefer IYH over chasing IBB’s trailing outperformance; treat IYH as a diversified sector allocation, not as a low-concentration substitute, given its LLY and top-holding weights.
• If seeking biotech upside, use IBB as a smaller satellite rather than a core holding. Its historical drawdown profile and clinical-event gap risk warrant sizing by potential loss, not by the reported beta alone.
• A conditional relative-value trade is long IYH / short IBB only if IBB’s relative strength rolls over; keep the position modest and assess the hedge using current holdings and realized covariance rather than assuming the reported S&P betas are a valid hedge ratio. No short is warranted solely from the trailing-return comparison.
• Reassess on broad-based IBB earnings or guidance improvement, sustained relative-strength breaks, and material FDA or M&A developments. Verify valuation, flows, and index exposures before adding risk; the supplied data do not establish that recent returns reflect durable earnings revisions.